Literature DB >> 12442913

The peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in human heart ventricles.

Mohammad R Mehrabi1, Theresia Thalhammer, Petra Haslmayer, Helmut D Glogar, Georg Wieselthaler, Susanne Humpeler, Wolfgang Marktl, Cem Ekmekcioglu.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand activated transcription factor which regulates gene expression in various tissues. PPARgamma was primarily found to be associated with lipid and glucose metabolism. Recent experimental studies provided evidence that PPARgamma is also expressed in the arterial wall and in cardiomyocytes and described PPARgamma as a transducer of antihypertropic signaling in the heart. This comparative study sought to investigate whether PPARgamma is differently expressed in the aorta, coronary arteries and left ventricle specimens derived from healthy heart donors (n = 5). By using quantitative PCR, we found that PPARgamma is expressed in all of the human specimens with the by far highest expression (5.01-fold) in the left ventricles compared to aorta, whereas no significant difference was detected between coronary arteries (0.93-fold) vs. aorta. Furthermore, especially great interindividual variations were observed in PPARgamma expression in aorta, and to a lesser extent, in coronary arteries and left ventricle specimens. In conclusion, our data argue for the prominent role of PPARgamma in the human heart, particularly in the normal left ventricle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12442913     DOI: 10.1016/s0753-3322(02)00251-2

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Conditional PPARγ knockout from cardiomyocytes of adult mice impairs myocardial fatty acid utilization and cardiac function.

Authors:  Jinwen Luo; Sijie Wu; Jian Liu; Yuquan Li; Huan Yang; Teayoun Kim; Olga Zhelyabovska; Guoliang Ding; Yiqun Zhou; Yifeng Yang; Qinglin Yang
Journal:  Am J Transl Res       Date:  2010-10-01       Impact factor: 4.060

2.  Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

Authors:  Hiroshi Hasegawa; Hiroyuki Takano; Issei Komuro
Journal:  PPAR Res       Date:  2010-08-12       Impact factor: 4.964

3.  PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting.

Authors:  Izabela Wojtkowska; Andrzej Tysarowski; Katarzyna Seliga; Janusz A Siedlecki; Zbigniew Juraszyński; Milosz Marona; Lidia Greszata; Anna Skrobisz; Karol Kaminski; Robert Sawicki; Janina Stępińska
Journal:  PPAR Res       Date:  2014-10-13       Impact factor: 4.964

4.  The implication of cigarette smoking and cessation on macrophage cholesterol efflux in coronary artery disease patients.

Authors:  Wei Song; Wei Wang; Li-Yang Dou; Yu Wang; Yan Xu; Lian-Feng Chen; Xiao-Wei Yan
Journal:  J Lipid Res       Date:  2015-01-19       Impact factor: 5.922

5.  Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.

Authors:  Eileen R Blasi; Jonathan Heyen; Michelle Hemkens; Aileen McHarg; Carolyn M Ecelbarger; Swasti Tiwari
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

6.  Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-γ expression and suppressing AP-1 activity.

Authors:  Lei Yan; Ji Dong Zhang; Bo Wang; Yi Jing Lv; Hong Jiang; Gui Lin Liu; Yun Qiao; Ming Ren; Xue Feng Guo
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

7.  Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte Differentiation.

Authors:  Maryam Peymani; Kamran Ghaedi; Shiva Irani; Mohammad Hossein Nasr-Esfahani
Journal:  Cell J       Date:  2016-05-30       Impact factor: 2.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.